{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:33:25Z","timestamp":1790660005406,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, & Immunity - Health"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bbih.2021.100307","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T02:18:13Z","timestamp":1627697893000},"page":"100307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Transport study of interleukin-1 inhibitors using a human in vitro model of the blood-brain barrier"],"prefix":"10.1016","volume":"16","author":[{"given":"Elisabet O.","family":"Sj\u00f6str\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Culot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9549-7934","authenticated-orcid":false,"given":"Lisa","family":"Leickt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"\u00c5strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9310-7947","authenticated-orcid":false,"given":"Erik","family":"Nordling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0481-5026","authenticated-orcid":false,"given":"Fabien","family":"Gosselet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7499-6769","authenticated-orcid":false,"given":"Christina","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbih.2021.100307_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte\u2013endothelial interactions at the blood\u2013brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbih.2021.100307_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nri1664","article-title":"Interleukin-1 and neuronal injury","volume":"5","author":"Allan","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbih.2021.100307_bib3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood\u2013brain barrier to blood\u2013brain interface: new opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbih.2021.100307_bib4","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1523\/JNEUROSCI.22-14-06071.2002","article-title":"The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury","volume":"22","author":"Basu","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.bbih.2021.100307_bib5","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1523\/JNEUROSCI.21-15-05528.2001","article-title":"Role of IL-1\u03b1 and IL-1\u03b2 in ischemic brain damage","volume":"21","author":"Boutin","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.bbih.2021.100307_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/iub.1377","article-title":"Interleukin-1\u03b1 and brain inflammation","volume":"67","author":"Brough","year":"2015","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bbih.2021.100307_bib7","doi-asserted-by":"crossref","first-page":"e99733","DOI":"10.1371\/journal.pone.0099733","article-title":"A\u00a0stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells","volume":"9","author":"Cecchelli","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.bbih.2021.100307_bib8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody","volume":"51","author":"Chakraborty","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbih.2021.100307_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.jcbfm.9600537","article-title":"Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations","volume":"28","author":"Clark","year":"2007","journal-title":"J.\u00a0Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.bbih.2021.100307_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/ana.25439","article-title":"Functional deficiency in endogenous interleukin-1 receptor antagonist in patients with febrile infection-related epilepsy syndrome","volume":"85","author":"Clarkson","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbih.2021.100307_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1460-9568.2011.07723.x","article-title":"Neutralization of interleukin-1\u03b2 reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice","volume":"34","author":"Clausen","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbih.2021.100307_bib12","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/j.1471-4159.1992.tb10055.x","article-title":"Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models","volume":"5","author":"Dehouck","year":"1992","journal-title":"J.\u00a0Neurochem."},{"issue":"38","key":"10.1016\/j.bbih.2021.100307_bib13","article-title":"Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade","volume":"15","author":"DeSena","year":"2018","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.bbih.2021.100307_bib14","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbih.2021.100307_bib15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbih.2021.100307_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jnc.13607","article-title":"Neuroinflammation: the devil is in the details","volume":"139","author":"DiSabato","year":"2016","journal-title":"J.\u00a0Neurochem."},{"issue":"1366","key":"10.1016\/j.bbih.2021.100307_bib17","article-title":"A\u00a0randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients","volume":"76","author":"Emsley","year":"2005","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.bbih.2021.100307_bib18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/jcbfm.2010.103","article-title":"Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study","volume":"31","author":"Galea","year":"2010","journal-title":"J.\u00a0Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.bbih.2021.100307_bib19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3171\/2016.9.JNS16615","article-title":"Reduction of inflammation after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid hemorrhage: results of the Subcutaneous Interleukin-1Ra in SAH (SCIL-SAH) study","volume":"128","author":"Galea","year":"2018","journal-title":"J.\u00a0Neurosurg."},{"key":"10.1016\/j.bbih.2021.100307_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.neuroimage.2004.09.034","article-title":"Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study","volume":"24","author":"Gerhard","year":"2005","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbih.2021.100307_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1476-5381.2010.00684.x","article-title":"Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection","volume":"160","author":"Greenhalgh","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbih.2021.100307_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2125.2007.03026.x","article-title":"Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage","volume":"65","author":"Gueorguieva","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbih.2021.100307_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-5728(94)90005-1","article-title":"Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier","volume":"55","author":"Gutierrez","year":"1994","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.bbih.2021.100307_bib24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/343336a0","article-title":"Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor","volume":"343","author":"Hannum","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bbih.2021.100307_bib25","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/0271678X16630991","article-title":"In vitro models of the blood\u2013brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use","volume":"36","author":"Helms","year":"2016","journal-title":"J.\u00a0Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.bbih.2021.100307_bib26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/jcbfm.2014.23","article-title":"Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial","volume":"34","author":"Helmy","year":"2014","journal-title":"J.\u00a0Cerebr. Blood Flow Metabol."},{"issue":"26","key":"10.1016\/j.bbih.2021.100307_bib27","article-title":"Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence","volume":"11","author":"Hladky","year":"2014","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.bbih.2021.100307_bib28","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1089\/neu.2007.0295","article-title":"Inflammation in human brain injury intracerebral concentrations of IL-1, IL-1, and their endogenous inhibitor IL-1ra","volume":"24","author":"Hutchinson","year":"2007","journal-title":"J.\u00a0Neurotrauma"},{"key":"10.1016\/j.bbih.2021.100307_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbih.2021.100307_bib30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ana.24806","article-title":"Febrile infection-related epilepsy syndrome treated with anakinra","volume":"80","author":"Kenney-Jung","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbih.2021.100307_bib31","series-title":"Swedish orphan Biovitrum AB (publ)","author":"Kineret Summary of Product Characteristics","year":"2020"},{"key":"10.1016\/j.bbih.2021.100307_bib32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/epi4.12447","article-title":"Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): a Report from FIRES workshop","volume":"6","author":"Koh","year":"2021","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.bbih.2021.100307_bib33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/cne.20052","article-title":"Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli","volume":"472","author":"Konsman","year":"2004","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.bbih.2021.100307_bib34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/HTR.0000000000000067","article-title":"Chronic inflammation after severe traumatic brain injury","volume":"30","author":"Kumar","year":"2015","journal-title":"J.\u00a0Head Trauma Rehabil."},{"key":"10.1016\/j.bbih.2021.100307_bib35","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1161\/01.STR.0000182255.08162.6a","article-title":"Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection","volume":"36","author":"Lazovic","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.bbih.2021.100307_bib36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/CIRCULATIONAHA.120.046301","article-title":"Postischemic administration of IL-1\u03b1 neutralizing antibody reduces brain damage and neurological deficit in experimental stroke","volume":"142","author":"Liberale","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.bbih.2021.100307_bib37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00401-018-1815-1","article-title":"Functional morphology of the blood\u2013brain barrier in health and disease","volume":"135","author":"Liebner","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"591","key":"10.1016\/j.bbih.2021.100307_bib38","article-title":"Structural, molecular, and functional alterations of the blood-brain barrier during epileptogenesis and epilepsy: a cause, consequence, or both?","volume":"21","author":"L\u00f6scher","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"186","key":"10.1016\/j.bbih.2021.100307_bib39","article-title":"Interleukin-1\u03b1 expression precedes IL-1\u03b2 after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues","volume":"8","author":"Luheshi","year":"2011","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.bbih.2021.100307_bib40","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0271678X15606714","article-title":"A\u00a0cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke","volume":"36","author":"Maysami","year":"2015","journal-title":"J.\u00a0Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.bbih.2021.100307_bib41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s12975-016-0489-z","article-title":"Systematic review and meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke: an update","volume":"7","author":"McCann","year":"2016","journal-title":"Transl Stroke Res"},{"issue":"18","key":"10.1016\/j.bbih.2021.100307_bib42","article-title":"Interleukin-1 and acute brain injury","volume":"9","author":"Murray","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bbih.2021.100307_bib43","first-page":"17","article-title":"Combined blockade of interleukin-1 \u03b1 and \u03b2 signaling protects mice from cognitive dysfunction after traumatic brain injury","author":"Newell","year":"2018","journal-title":"Eneuro 5, ENEURO"},{"issue":"387","key":"10.1016\/j.bbih.2021.100307_bib44","article-title":"Interleukin-1 beta neutralization attenuates traumatic brain injury-induced microglia activation and neuronal changes in the globus pallidus","volume":"21","author":"Ozen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbih.2021.100307_bib45","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood\u2013brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J.\u00a0Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.bbih.2021.100307_bib46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0040-1708503","article-title":"Extinguishing febrile infection-related epilepsy syndrome: pipe dream or reality?","volume":"40","author":"Payne","year":"2020","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.bbih.2021.100307_bib47","doi-asserted-by":"crossref","first-page":"e16114","DOI":"10.1371\/journal.pone.0016114","article-title":"Improved survival, vascular differentiation and wound healing potential of stem cells Co-cultured with endothelial cells","volume":"6","author":"Pedroso","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.bbih.2021.100307_bib48","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1471-4159.2002.01184.x","article-title":"Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells","volume":"83","author":"Pinteaux","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.bbih.2021.100307_bib49","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1073\/pnas.91.12.5705","article-title":"Macromolecular permeability across the blood-nerve and blood-brain barriers","volume":"91","author":"Poduslo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.bbih.2021.100307_bib50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbi.2016.11.013","article-title":"Reparative effects of interleukin-1 receptor antagonist in young and aged\/co-morbid rodents after cerebral ischemia","volume":"61","author":"Pradillo","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbih.2021.100307_bib51","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/exnr.1996.0059","article-title":"Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat","volume":"138","author":"Relton","year":"1996","journal-title":"Exp. Neurol."},{"issue":"820","key":"10.1016\/j.bbih.2021.100307_bib52","article-title":"Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus","volume":"86","author":"Sakuma","year":"2015","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.bbih.2021.100307_bib53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/mabs.23684","article-title":"Antibody biodistribution coefficients","volume":"5","author":"Shah","year":"2013","journal-title":"Mabs"},{"issue":"1714","key":"10.1016\/j.bbih.2021.100307_bib54","article-title":"A\u00a024-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease","volume":"74","author":"Sibley","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbih.2021.100307_bib55","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bbih.2021.100307_bib56","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1476-5381.2008.00129.x","article-title":"Transport of interleukin-1 across cerebromicrovascular endothelial cells","volume":"156","author":"Skinner","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbih.2021.100307_bib57","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/labinvest.2016.35","article-title":"Adapting coculture in vitro models of the blood\u2013brain barrier for use in cancer research: maintaining an appropriate endothelial monolayer for the assessment of transendothelial migration","volume":"96","author":"Vandenhaute","year":"2016","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bbih.2021.100307_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","article-title":"The role of inflammation in epilepsy","volume":"7","author":"Vezzani","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.bbih.2021.100307_bib59","article-title":"Inflammation in epileptogenesis after traumatic brain injury","volume":"14","author":"Webster","year":"2017","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.bbih.2021.100307_bib60","first-page":"135","article-title":"Febrile infection-related epilepsy syndrome treated successfully with anakinra in a 21-year-old woman","volume":"118","author":"Westbrook","year":"2019","journal-title":"Wmj Official Publ State Medical Soc Wis"},{"key":"10.1016\/j.bbih.2021.100307_bib61","doi-asserted-by":"crossref","first-page":"e1000145","DOI":"10.1371\/journal.pmed.1000145","article-title":"Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6","volume":"6","author":"Whiteley","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.bbih.2021.100307_bib62","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/01.STR.26.4.676","article-title":"Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats","volume":"26","author":"Yamasaki","year":"1995","journal-title":"Stroke"}],"container-title":["Brain, Behavior, & Immunity - Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354621001101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354621001101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:28:26Z","timestamp":1762986506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666354621001101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":62,"alternative-id":["S2666354621001101"],"URL":"https:\/\/doi.org\/10.1016\/j.bbih.2021.100307","relation":{},"ISSN":["2666-3546"],"issn-type":[{"value":"2666-3546","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transport study of interleukin-1 inhibitors using a human in vitro model of the blood-brain barrier","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, & Immunity - Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbih.2021.100307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100307"}}